Global Motion Sickness Treatment Market

Motion Sickness Treatment Comprehensive Study by Type (Anticholinergic, Antihistamines), Route of Administration (Oral, Transdermal, Parenteral, Other), Distribution Channel (Retail Pharmacies, Online Pharmacies, Others) Players and Region - Global Market Outlook to 2026

Motion Sickness Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Motion sickness is a common condition characterized by a set of symptoms such as dizziness, nausea, and fatigue experienced by a person while traveling. It is caused by differences in impulses received by the perceived sense of motion by visual senses and the vestibular system’s sense of movement. Various prescription and OTC drugs and products are used to treat motion sickness and provide relief from their symptoms. Anticholinergic, antihistamines, and sympathomimetic are the most commonly used medications.This growth is primarily driven by Increased Number of Travellers and Virtual Reality Exposure Across the Globe and Rising Adoption of Prescription Motion Sickness Drugs.

Globally, a noticeable market trend is evident Advent of Nauseogenic Information Technology. Major Players, such as GlaxoSmithKline plc (United Kingdom), Perrigo Company plc (Ireland), Prestige Brands (United States), WellSpring Pharmaceutical Corporation (United States), Caleb Pharmaceuticals (Taiwan), Myungmoon Pharm Co. (South Korea), Baxter International (United States), Reliefband Technologies LLC. (United States) and CVS Health (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Market Drivers
  • Increased Number of Travellers and Virtual Reality Exposure Across the Globe
  • Rising Adoption of Prescription Motion Sickness Drugs

Market Trend
  • Advent of Nauseogenic Information Technology

Restraints
  • Reluctance in Emerging Countries due to Higher Cost of Prescription Drugs
  • Excessive Reliance on the OTC and Traditional Medicines

Opportunities
Increase in Awareness of the Disease and Rising in the Number of Domestic and International Travelers
Challenges
Stringent Government Rules and Regulations

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Motion Sickness Treatment Study Sheds Light on
— The Motion Sickness Treatment Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Motion Sickness Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Motion Sickness Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Anticholinergic
  • Antihistamines
By Route of Administration
  • Oral
  • Transdermal
  • Parenteral
  • Other

By Distribution Channel
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Number of Travellers and Virtual Reality Exposure Across the Globe
      • 3.2.2. Rising Adoption of Prescription Motion Sickness Drugs
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Advent of Nauseogenic Information Technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Motion Sickness Treatment, by Type, Route of Administration, Distribution Channel and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Motion Sickness Treatment (Value)
      • 5.2.1. Global Motion Sickness Treatment by: Type (Value)
        • 5.2.1.1. Anticholinergic
        • 5.2.1.2. Antihistamines
      • 5.2.2. Global Motion Sickness Treatment by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Transdermal
        • 5.2.2.3. Parenteral
        • 5.2.2.4. Other
      • 5.2.3. Global Motion Sickness Treatment by: Distribution Channel (Value)
        • 5.2.3.1. Retail Pharmacies
        • 5.2.3.2. Online Pharmacies
        • 5.2.3.3. Others
      • 5.2.4. Global Motion Sickness Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Motion Sickness Treatment (Price)
      • 5.3.1. Global Motion Sickness Treatment by: Type (Price)
  • 6. Motion Sickness Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Perrigo Company plc (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Prestige Brands (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. WellSpring Pharmaceutical Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Caleb Pharmaceuticals (Taiwan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Myungmoon Pharm Co. (South Korea)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Baxter International (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Reliefband Technologies LLC. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. CVS Health (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Motion Sickness Treatment Sale, by Type, Route of Administration, Distribution Channel and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Motion Sickness Treatment (Value)
      • 7.2.1. Global Motion Sickness Treatment by: Type (Value)
        • 7.2.1.1. Anticholinergic
        • 7.2.1.2. Antihistamines
      • 7.2.2. Global Motion Sickness Treatment by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Transdermal
        • 7.2.2.3. Parenteral
        • 7.2.2.4. Other
      • 7.2.3. Global Motion Sickness Treatment by: Distribution Channel (Value)
        • 7.2.3.1. Retail Pharmacies
        • 7.2.3.2. Online Pharmacies
        • 7.2.3.3. Others
      • 7.2.4. Global Motion Sickness Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Motion Sickness Treatment (Price)
      • 7.3.1. Global Motion Sickness Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Motion Sickness Treatment: by Type(USD Million)
  • Table 2. Motion Sickness Treatment Anticholinergic , by Region USD Million (2015-2020)
  • Table 3. Motion Sickness Treatment Antihistamines , by Region USD Million (2015-2020)
  • Table 4. Motion Sickness Treatment: by Route of Administration(USD Million)
  • Table 5. Motion Sickness Treatment Oral , by Region USD Million (2015-2020)
  • Table 6. Motion Sickness Treatment Transdermal , by Region USD Million (2015-2020)
  • Table 7. Motion Sickness Treatment Parenteral , by Region USD Million (2015-2020)
  • Table 8. Motion Sickness Treatment Other , by Region USD Million (2015-2020)
  • Table 9. Motion Sickness Treatment: by Distribution Channel(USD Million)
  • Table 10. Motion Sickness Treatment Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 11. Motion Sickness Treatment Online Pharmacies , by Region USD Million (2015-2020)
  • Table 12. Motion Sickness Treatment Others , by Region USD Million (2015-2020)
  • Table 13. South America Motion Sickness Treatment, by Country USD Million (2015-2020)
  • Table 14. South America Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 15. South America Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 16. South America Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 17. Brazil Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 18. Brazil Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 19. Brazil Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 20. Argentina Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 21. Argentina Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 22. Argentina Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 23. Rest of South America Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 24. Rest of South America Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 25. Rest of South America Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 26. Asia Pacific Motion Sickness Treatment, by Country USD Million (2015-2020)
  • Table 27. Asia Pacific Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 28. Asia Pacific Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 29. Asia Pacific Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 30. China Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 31. China Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 32. China Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 33. Japan Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 34. Japan Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 35. Japan Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 36. India Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 37. India Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 38. India Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 39. South Korea Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 40. South Korea Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 41. South Korea Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 42. Taiwan Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 43. Taiwan Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 44. Taiwan Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 45. Australia Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 46. Australia Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 47. Australia Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 51. Europe Motion Sickness Treatment, by Country USD Million (2015-2020)
  • Table 52. Europe Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 53. Europe Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 54. Europe Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 55. Germany Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 56. Germany Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 57. Germany Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 58. France Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 59. France Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 60. France Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 61. Italy Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 62. Italy Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 63. Italy Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 64. United Kingdom Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 65. United Kingdom Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 66. United Kingdom Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 67. Netherlands Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 68. Netherlands Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 69. Netherlands Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 70. Rest of Europe Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 71. Rest of Europe Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 72. Rest of Europe Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 73. MEA Motion Sickness Treatment, by Country USD Million (2015-2020)
  • Table 74. MEA Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 75. MEA Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 76. MEA Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 77. Middle East Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 78. Middle East Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 79. Middle East Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 80. Africa Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 81. Africa Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 82. Africa Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 83. North America Motion Sickness Treatment, by Country USD Million (2015-2020)
  • Table 84. North America Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 85. North America Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 86. North America Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 87. United States Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 88. United States Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 89. United States Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 90. Canada Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 91. Canada Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 92. Canada Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 93. Mexico Motion Sickness Treatment, by Type USD Million (2015-2020)
  • Table 94. Mexico Motion Sickness Treatment, by Route of Administration USD Million (2015-2020)
  • Table 95. Mexico Motion Sickness Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 96. Motion Sickness Treatment: by Type(USD/Units)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Motion Sickness Treatment: by Type(USD Million)
  • Table 107. Motion Sickness Treatment Anticholinergic , by Region USD Million (2021-2026)
  • Table 108. Motion Sickness Treatment Antihistamines , by Region USD Million (2021-2026)
  • Table 109. Motion Sickness Treatment: by Route of Administration(USD Million)
  • Table 110. Motion Sickness Treatment Oral , by Region USD Million (2021-2026)
  • Table 111. Motion Sickness Treatment Transdermal , by Region USD Million (2021-2026)
  • Table 112. Motion Sickness Treatment Parenteral , by Region USD Million (2021-2026)
  • Table 113. Motion Sickness Treatment Other , by Region USD Million (2021-2026)
  • Table 114. Motion Sickness Treatment: by Distribution Channel(USD Million)
  • Table 115. Motion Sickness Treatment Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 116. Motion Sickness Treatment Online Pharmacies , by Region USD Million (2021-2026)
  • Table 117. Motion Sickness Treatment Others , by Region USD Million (2021-2026)
  • Table 118. South America Motion Sickness Treatment, by Country USD Million (2021-2026)
  • Table 119. South America Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 120. South America Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 121. South America Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 122. Brazil Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 123. Brazil Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 124. Brazil Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 125. Argentina Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 126. Argentina Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 127. Argentina Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 128. Rest of South America Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 129. Rest of South America Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 130. Rest of South America Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 131. Asia Pacific Motion Sickness Treatment, by Country USD Million (2021-2026)
  • Table 132. Asia Pacific Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 133. Asia Pacific Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 134. Asia Pacific Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 135. China Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 136. China Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 137. China Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 138. Japan Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 139. Japan Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 140. Japan Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 141. India Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 142. India Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 143. India Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 144. South Korea Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 145. South Korea Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 146. South Korea Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 147. Taiwan Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 148. Taiwan Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 149. Taiwan Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 150. Australia Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 151. Australia Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 152. Australia Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 153. Rest of Asia-Pacific Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 154. Rest of Asia-Pacific Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 155. Rest of Asia-Pacific Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 156. Europe Motion Sickness Treatment, by Country USD Million (2021-2026)
  • Table 157. Europe Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 158. Europe Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 159. Europe Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 160. Germany Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 161. Germany Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 162. Germany Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 163. France Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 164. France Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 165. France Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 166. Italy Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 167. Italy Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 168. Italy Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 169. United Kingdom Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 170. United Kingdom Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 171. United Kingdom Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 172. Netherlands Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 173. Netherlands Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 174. Netherlands Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 175. Rest of Europe Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 176. Rest of Europe Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 177. Rest of Europe Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 178. MEA Motion Sickness Treatment, by Country USD Million (2021-2026)
  • Table 179. MEA Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 180. MEA Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 181. MEA Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 182. Middle East Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 183. Middle East Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 184. Middle East Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 185. Africa Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 186. Africa Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 187. Africa Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 188. North America Motion Sickness Treatment, by Country USD Million (2021-2026)
  • Table 189. North America Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 190. North America Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 191. North America Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 192. United States Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 193. United States Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 194. United States Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 195. Canada Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 196. Canada Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 197. Canada Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 198. Mexico Motion Sickness Treatment, by Type USD Million (2021-2026)
  • Table 199. Mexico Motion Sickness Treatment, by Route of Administration USD Million (2021-2026)
  • Table 200. Mexico Motion Sickness Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 201. Motion Sickness Treatment: by Type(USD/Units)
  • Table 202. Research Programs/Design for This Report
  • Table 203. Key Data Information from Secondary Sources
  • Table 204. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Motion Sickness Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Motion Sickness Treatment: by Route of Administration USD Million (2015-2020)
  • Figure 6. Global Motion Sickness Treatment: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Motion Sickness Treatment Share (%), by Country
  • Figure 8. Asia Pacific Motion Sickness Treatment Share (%), by Country
  • Figure 9. Europe Motion Sickness Treatment Share (%), by Country
  • Figure 10. MEA Motion Sickness Treatment Share (%), by Country
  • Figure 11. North America Motion Sickness Treatment Share (%), by Country
  • Figure 12. Global Motion Sickness Treatment: by Type USD/Units (2015-2020)
  • Figure 13. Global Motion Sickness Treatment share by Players 2020 (%)
  • Figure 14. Global Motion Sickness Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Motion Sickness Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Perrigo Company plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 20. Perrigo Company plc (Ireland) Revenue: by Geography 2020
  • Figure 21. Prestige Brands (United States) Revenue, Net Income and Gross profit
  • Figure 22. Prestige Brands (United States) Revenue: by Geography 2020
  • Figure 23. WellSpring Pharmaceutical Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 24. WellSpring Pharmaceutical Corporation (United States) Revenue: by Geography 2020
  • Figure 25. Caleb Pharmaceuticals (Taiwan) Revenue, Net Income and Gross profit
  • Figure 26. Caleb Pharmaceuticals (Taiwan) Revenue: by Geography 2020
  • Figure 27. Myungmoon Pharm Co. (South Korea) Revenue, Net Income and Gross profit
  • Figure 28. Myungmoon Pharm Co. (South Korea) Revenue: by Geography 2020
  • Figure 29. Baxter International (United States) Revenue, Net Income and Gross profit
  • Figure 30. Baxter International (United States) Revenue: by Geography 2020
  • Figure 31. Reliefband Technologies LLC. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Reliefband Technologies LLC. (United States) Revenue: by Geography 2020
  • Figure 33. CVS Health (United States) Revenue, Net Income and Gross profit
  • Figure 34. CVS Health (United States) Revenue: by Geography 2020
  • Figure 35. Global Motion Sickness Treatment: by Type USD Million (2021-2026)
  • Figure 36. Global Motion Sickness Treatment: by Route of Administration USD Million (2021-2026)
  • Figure 37. Global Motion Sickness Treatment: by Distribution Channel USD Million (2021-2026)
  • Figure 38. South America Motion Sickness Treatment Share (%), by Country
  • Figure 39. Asia Pacific Motion Sickness Treatment Share (%), by Country
  • Figure 40. Europe Motion Sickness Treatment Share (%), by Country
  • Figure 41. MEA Motion Sickness Treatment Share (%), by Country
  • Figure 42. North America Motion Sickness Treatment Share (%), by Country
  • Figure 43. Global Motion Sickness Treatment: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc (United Kingdom)
  • Perrigo Company plc (Ireland)
  • Prestige Brands (United States)
  • WellSpring Pharmaceutical Corporation (United States)
  • Caleb Pharmaceuticals (Taiwan)
  • Myungmoon Pharm Co. (South Korea)
  • Baxter International (United States)
  • Reliefband Technologies LLC. (United States)
  • CVS Health (United States)
Select User Access Type

Key Highlights of Report


Jan 2022 214 Pages 78 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Motion Sickness Treatment Market Quantitative research analysis
Global Motion Sickness Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Motion Sickness Treatment Market are GlaxoSmithKline plc (United Kingdom), Perrigo Company plc (Ireland), Prestige Brands (United States), WellSpring Pharmaceutical Corporation (United States), Caleb Pharmaceuticals (Taiwan), Myungmoon Pharm Co. (South Korea), Baxter International (United States), Reliefband Technologies LLC. (United States) and CVS Health (United States) etc.
Motion sickness is a common condition characterized by a set of symptoms such as dizziness, nausea, and fatigue experienced by a person while traveling. It is caused by differences in impulses received by the perceived sense of motion by visual senses and the vestibular system’s sense of movement. Various prescription and OTC drugs and products are used to treat motion sickness and provide relief from their symptoms. Anticholinergic, antihistamines, and sympathomimetic are the most commonly used medications.

Know More About Global Motion Sickness Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Sickle Cell Anemia Drug Comprehensive Study by Type (Antibiotics, Hydroxyurea, Pain-relieving medications, Others), Mode of Administration (Oral, Intravenous), Disease Type (Sickle cell anemia, Sickl...
$ 3650
Multiple Sclerosis Comprehensive Study by Type (Clinically Isolated Syndrome, Relapsing-remitting, Secondary progressive, Primary progressive, Progressive-relapsing), Distribution Channel (Hospitals ...
$ 3800
Folinic Acid Comprehensive Study by Application (Hospitals, Pharmaceuticals, Nutraceutical, Food and Beverages, Others), Form (Tablets, Injection, Others), Distribution Channels (Online, Offline) Pla...
$ 3500
Ipecac Comprehensive Study by Type (Powder, Liquid (Syrup)), Application (Hospitals, Clinics), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2024
$ 3500
Kidney Detox Comprehensive Study by Type (Tablets, Capsules), Distribution Channel (Direct sales, Indirect sales), Industry Segmentation (Hospitals, Individuals) Players and Region - Global Market O...
$ 3500
Betaxolol Comprehensive Study by Form (Solution/Suspension, Film-Coated Tablets), Distribution Channels (Hospitals, Medical Pharmacy, Online Medical Store), Disease Indication (Glaucoma, Hypertension...
$ 3350